Calcium Composition with TRP Agonist for Rumen Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional calcium compositions for treating animals with milk fever have limited calcium uptake, leading to mucosal damage and increased systemic toxin uptake, and require multiple administrations, which can cause erosive effects and acidosis.
Innovation Solution
A composition comprising a calcium source and a TRP agonist, such as menthol, with a calcium content of at least 5 wt % based on the total weight, which increases calcium flux through the mucosal wall, reducing the need for multiple administrations and minimizing mucosal damage by decreasing paracellular flux.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional calcium preparations are administered to increase calcium levels in blood plasma, then calcium uptake is achieved, but mucosal damage and increased systemic toxin uptake occur
Solution Approach 1:
The TRP agonist acts as an intermediary substance that mediates between the calcium preparation and the ruminal mucosa. It activates TRP channels to increase calcium flux through the mucosal wall while simultaneously reducing paracellular flux, thereby facilitating calcium uptake without causing mucosal damage or toxin leakage
Solution Approach 2:
The invention changes the physiological parameters of the ruminal mucosa by activating TRP channels. This activation modifies the transport properties of the mucosal wall, increasing calcium permeability while decreasing paracellular flux, thus resolving the contradiction between calcium uptake and mucosal integrity
2Duration of action of moving object
If multiple administrations of calcium preparations are performed to maintain calcium levels, then calcium supplementation is ensured, but erosive effects on the mucosa and acidosis increase
Solution Approach 1:
The TRP agonist serves as a mediator that enables a single administration to achieve sustained calcium supplementation. By activating TRP channels, it prolongs calcium flux through the mucosal wall, reducing the frequency of administrations needed and thereby minimizing cumulative erosive effects and acidosis risk
Solution Approach 2:
The TRP agonist ensures continuous calcium uptake by maintaining activated TRP channels over an extended period. This continuous action allows for less frequent administrations while ensuring sustained calcium supplementation, reducing the harmful effects associated with multiple doses
3Speed
If higher amounts of calcium are administered to achieve faster calcium levels in blood plasma, then calcium uptake speed increases, but mucosal damage and toxin uptake increase
Solution Approach 1:
The TRP agonist acts as a mediator that decouples calcium uptake speed from calcium amount. By activating TRP channels, it accelerates calcium flux through the mucosal wall without requiring higher calcium doses, thus achieving fast calcium levels while protecting the mucosa from damage
Solution Approach 2:
The invention changes the transport parameter of the mucosal wall by activating TRP channels. This parameter change increases calcium permeability, allowing faster calcium uptake with lower calcium amounts, thereby resolving the contradiction between uptake speed and mucosal integrity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enhances calcium levels in blood plasma faster and reduces the risk of mucosal damage and systemic toxin uptake, allowing for lower calcium amounts and fewer administrations while maintaining effective calcium delivery.
Implementation Method 1
The TRP agonist of the invention enables the calcium to be taken up in the rumen more easily by increasing the calcium flux through the mucosal wall
Implementation Method 2
the use of the TRP agonist was shown to reduce the paracellular flux of the mucosal epithelium which causes the mucosal epithelial cells to be less prone to damage
Data Source
AI summary
The present invention pertains to a composition comprising a calcium source, a TRP agonist, water and optionally an excipient, wherein the amount of the calcium source is at least 5 wt %, based on the total weight of the composition.